adoptive T-cell therapy targeting KRas (Zelluna Immunotherapy)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameadoptive T-cell therapy targeting KRas (Zelluna Immunotherapy)
Drug Alias Nameanti-KRas ACT (Zelluna Immunotherapy)anti-KRas CAR T-cell therapy (Zelluna)anti-KRas TCR adoptive T-cell therapy (Zelluna)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog modulators
TargetsGTPase KRas
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNorway
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesZelluna Immunotherapy AS
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesZelluna Immunotherapy AS
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A